“By partnering with LEO Pharma, we hope to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions.” Bank of ...

The company believes that the STAT6 program stands out as a promising ... bispecifics targeting multiple key disease-driving pathways in treating AD and other immune-mediated diseases.